Australia markets closed

Castle Biosciences, Inc. (CSTL)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
35.71+0.27 (+0.76%)
As of 03:47PM EST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 1.03B
Enterprise value 864.57M
Trailing P/E 478.00
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)11.27
Price/book (mrq)2.49
Enterprise value/revenue 10.01
Enterprise value/EBITDA -31.84

Trading information

Stock price history

Beta (5Y monthly) 0.58
52-week change 3-50.06%
S&P500 52-week change 314.56%
52-week high 3107.69
52-week low 331.46
50-day moving average 342.18
200-day moving average 360.75

Share statistics

Avg vol (3-month) 3243.02k
Avg vol (10-day) 3252.81k
Shares outstanding 525.3M
Implied shares outstanding 6N/A
Float 823.77M
% held by insiders 19.42%
% held by institutions 187.62%
Shares short (30 Dec 2021) 4962.77k
Short ratio (30 Dec 2021) 43.81
Short % of float (30 Dec 2021) 44.98%
Short % of shares outstanding (30 Dec 2021) 43.81%
Shares short (prior month 29 Nov 2021) 41.04M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Sept 2021

Profitability

Profit margin -34.46%
Operating margin (ttm)-34.54%

Management effectiveness

Return on assets (ttm)-5.79%
Return on equity (ttm)-10.29%

Income statement

Revenue (ttm)86.34M
Revenue per share (ttm)3.60
Quarterly revenue growth (yoy)54.30%
Gross profit (ttm)52.96M
EBITDA -28.66M
Net income avi to common (ttm)-29.75M
Diluted EPS (ttm)-1.24
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)363.18M
Total cash per share (mrq)14.35
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)18.56
Book value per share (mrq)16.28

Cash flow statement

Operating cash flow (ttm)-16.63M
Levered free cash flow (ttm)-9.56M